Acute aortic arch dissection: reevaluation of the indications for medical and surgical therapy.

Of 42 patients with dissection of the aorta, 4 had important arch involvement. Results were good in 2 patients treated medically. In two other patients wrapping the arch with a Dacron graft successfully prevented fatal hemorrhage. This technique avoids the need for arch replacement in selected cases. From this experience and a review of others a flow sheet was developed to guide decision-making in the surgical and medical management of patients with aortic dissection.

Thrombus generation within the artificial heart.

The sites of thrombus formation in the Jarvik III artificial heart were studied in 20 consecutive calf experiments. Identical design and implantation procedures were used with two different surfaces. The 10 anticoagulated calves receiving Dacron-fibrilized silicone rubber surfaces survived an average of 296 hours. In contrast, the 10 nonanticoagulated calves with smooth poyurethane hearts survived 545 hours. The polyurethane surfaces were constantly clean. However, the rough surfaces were coated with variable amounts of thrombi. The sharp angle between the diaphragm and housing contained varying amounts of thrombi deposits in 75 per cent of the cases. Thrombe deposition occurred on 41 per cent of the valves. These thrombe were the source of emboli into the kidney, brain, and lungs. Turbulences and stagnation areas generated thrombus formation. Anticoagulation did not prevent thrombus formation. It would appear that heart free of turbulence and stagnation areas must be designed to eliminate thromboembolism.

Transmyocardial laser revascularization: clinical experience with twelve-month follow-up.

We are investigating a new technique for myocardial revascularization in which an 800 W carbon dioxide laser is used to drill 1 mm diameter channels into a beating heart after left thoracotomy. Clotting occludes the channels on the subepicardium, and in the long-term setting, blood from the left ventricular cavity flows through these channels to perfuse the ischemic subendocardium. To test the efficacy of this technique in a preliminary clinical trial, we used it as sole therapy for 21 consecutive patients. All patients had hibernating myocardium, reduced coronary flow reserve, or both, had distal diffuse coronary artery disease, and had angina refractory to normal therapy. Eight patients were excluded from follow-up because of death (n=5), rerevascularization (n=2), or diaphragmatic paralysis resulting in postoperative respiratory incapacity (n=1). In the remaining 13 patients available for follow-up, the mean angina class (Canadian Cardiovascular Society) was 3.7 +/- 0.4 before operation and 1.8 +/- 0.6 12 months after operation (p < 0.01). Mean resting left ventricular ejection fraction was 48% +/- 10% before operation and 50% +/- 8% at 12-month follow-up. At 12 months, resting mean subendocardial/subepicardial perfusion ratio had increased by 20% +/- 9% in septal regions treated by laser but decreased by 2% +/- 5% in untreated regions (n=11, p <.001). These results suggest that revascularization by this laser technique positively affects subregional myocardial perfusion and may result in clinical benefits for patients with reversible myocardial ischemia. Studies to date have not demonstrated significant changes in global and regional ventricular contractile function.

The artificial heart in human subjects.

In preparation for clinical implantation of the Utah J-7 pneumatic artificial heart as a permanent cardiac substitute, the device was implanted into five brain-dead human subjects. This report presents our results and details our two most successful trials. Three different surgical implant techniques were utilized in the five subjects. Because of the unique "no risk" situation of the subjects, the function of the artificial heart could be tested in a manner not advisable in patients, but necessary for clinical preparation. The implantable total artificial heart was able to maintain physiological hemodynamics in two subjects for 41 and 72 hours at which time the trials were electively terminated.

Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators.

A prospective randomized trial involving 91 patients undergoing cardiopulmonary bypass compared the effects of bubble oxygenators (with and without methylprednisolone sodium succinate) and membrane oxygenators on complement activation and transpulmonary sequestration of leukocytes. Patients were divided as follows: Group I, 30 patients, bubble oxygenator; Group II, 31 patients, bubble oxygenator and methylprednisolone sodium succinate (30 mg/kg); Group III, 30 patients, membrane oxygenator. In Group I, C3a increased from 323 +/- 171 ng/ml during cardiopulmonary bypass to 1,564 +/- 785 ng/ml at 25 minutes after bypass (p less than 0.0001). A significant decrease in C3a was found in Groups II and III compared to Group I (p less than 0.0001). C5a did not change significantly during cardiopulmonary bypass in any group. Reestablishment of pulmonary circulation at the end of bypass produced significant transpulmonary leukocyte sequestration in Group I; the median cell difference was 1,700/microliter. Transpulmonary sequestration was significantly (p less than 0.0001) less in Group II (median cell difference = 200/microliter) and in Group III (median cell difference = 400/microliter) than in Group I. We conclude that cardiopulmonary bypass with a bubble oxygenator alone initiates significantly (p less than 0.0001) more C3a activation and leukocyte sequestration than when methylprednisolone sodium succinate (30 mg/kg) is given 20 minutes before the start of cardiopulmonary bypass with a bubble oxygenator or when a silicone membrane oxygenator is used.

Management of patent saphenous vein grafts during reoperative coronary artery bypass grafting.

A patient was referred for coronary artery bypass reoperation. After a left internal mammary artery was grafted to the left anterior descending coronary artery, the diseased but patent old saphenous vein graft was ligated. This resulted in severe myocardial failure, which was corrected only after restoration of flow through the old vein graft. We suggest the decision to ligate or replace an old vein graft should be individualized to avoid the risk of myocardial ischemia.

New technique for coronary sinus cannulation using a fiberoptic stylet.

Fluoroscopy, echocardiography, blind digital approach, and direct visual insertion have been used for retrograde cannulation of the coronary sinus. We cannulate the coronary sinus by transillumination using a standard flexible retroplegia cannula with a reusable fiberoptic stylet designed by our open heart program. An attachable light source illuminates the tip, which is guided into the coronary sinus ostium. We have used the technique in 16 patients who could not be cannulated with the blind digital method.

Silastic T tube splints for biliary repair.

Silastic rubber T tubes have been compared with latex rubber T tubes in the biliary system of dogs. It was found that Silastic rubber T tubes evoked a significant foreign body reaction within the biliary system, producing bile salt precipitation and debris. Alarmingly, in these studies in dogs, Silastic rubber T tubes did not cause sufficient intraperitoneal adhesions around the tube to form an intraperitoneal tract walling off the tube from the general peritoneal cavity. Thus, when the Silastic rubber T tube was removed, bile leakage into the peritoneal cavity occurred. Based on studies in dogs, Silastic rubber T tubes should not be used in the clinical situation in which the T tube would be removed postoperatively.

Artificial heart and left ventricular assist devices.

We believe there will be a place in cardiac surgery for a variety of assist and replacement devices. The extracorporeal assist devices, with or without extracorporeal membrane oxygenation, will be needed for acute situations requiring time for diagnosis and prognosis to be determined. There will also be a place for intrathoracic paraventricular assist devices that may temporarily or permanently support the right or left ventricle. Finally, we believe that there will be a number of patients whose native cardiac function is of no help at all and whose hearts probably should be removed to make room for an improved blood pump of human design. Pneumatic ventricles are presently available and we should see increasing use of them over the next couple of years. The convenience for a patient of electrical wires instead of pneumatic hoses coming out of the chest is obvious. However, the complexity and cost of the overall system is considerably greater, further testing and development is needed. Dr. William Pierce already has kept an animal alive for over 6 months with an electrically driven heart. Clearly, the electrically driven systems are the pumps for the next decade.

Results of the unidirectional Centri-Safe arterial valve for prevention of retrograde flow during cardiopulmonary bypass.

Retrograde blood from the aortic cannula into the cardiopulmonary circuit may lead to aortic air emboli when nonocclusive centrifugal pumps are used. The authors tested a nonregurgitant, unidirectional valve containing a Teflon ball occluder to prevent backflow. In vitro measurements of leakage rate, forward flow pressure drop, burst strength, and hemolysis levels along with animal (n = 12) and human (n = 12) in vivo hematologic and hemolysis levels were measured. Data were analyzed by paired and unpaired Student's t-test. Pressure drop differences at flows of 5 l/min were 7.3 +/- 0.3 mmHg before and 7.6 +/- 0.1 mmHg after 10,800 cycles of pulsatile pumping. (P = NS). Leakage rate during this period at pressures of 100 mmHg was not significant. Volume required to close the Teflon ball was less than 1 ml. Hemolysis analysis done in vitro and in vivo in control (no valve) and experimental (valve) groups used hemoglobin, hematocrit, platelets, plasma free hemoglobin, and lactic dehydrogenase as hemolysis indices. There were no statistical differences. The authors conclude that the CentriSafe valve (Cardiac Systems, Inc., Conshohocken, PA) is safe and prevents fatal backflow and air emboli. The valve is nonthrombotic in anticoagulated blood, can be opened and closed thousands of times, and has a burst strength equal to or greater than other components in the perfusion setup.

Five month survival in a calf supported with an intraventricular axial flow blood pump.

We are studying in vivo an intraventricular axial flow blood pump (Jarvik 2000) designed for long-term left ventricular support. The small (25 cc, 85 g) valveless pump has been placed intraventricularly in seven calves; pumps have functioned for as long as 5 months. In the four most recent long-term studies completed, calves have survived for 70, 120, 155, and 162 days (in that order); weight gain has averaged 0.56 kg/day. One study is ongoing at more than 30 days. Under resting physiologic conditions in the normal calf, the continuous flow pump produces flows of 5-6 L/min with a decreased arterial pulse contour. The device has caused no physiologic complications. Calves in the completed studies had mean free plasma hemoglobin levels of 11.4, 7.1, 6.5, and 4.3 mg/dl, respectively. We have modified the inflow structures of the device, and these results suggest that a thrombus free design with no pannus at or around the inlet of the pump can be achieved. Histopathologic analyses of the heart and kidneys in studies of as long as 5 months show no deleterious effects of this device. These studies demonstrate the feasibility of a small implanted intraventricular blood pump for long-term use. Future developments for permanent implantation will include implanted physiologic control systems, transcutaneous energy transmission systems, and implanted batteries.

Prosthetic valve endocarditis with annulus destruction: technique for reconstruction.

When endocarditis involves a mechanical prosthetic aortic valve, it is a certainty that the annulus is destroyed; the pathology may extend to produce aneurysms of the sinuses of Valsalva or progress to fistulization into juxtaposed cardiac chambers or the pericardium. Annular destruction breaks down the framework to which a new prosthesis is anchored; therefore, valve replacement requires the creation of a new annulus. This report describes the technique for reconstructing partial aortoventricular discontinuity caused by annular destruction from prosthetic valve bacterial endocarditis.

Centrifugal pump failures.

Centrifugal pumps will not pass gross quantities of gaseous emboli due to the nonocclusive nature of the pump. However, retrograde flow can occur under circumstances that include: product malfunctions, low flows, and human errors. Negative pressure created by falling arterial perfusate can draw air into the cannula. Food and Drug Administration (FDA) records about centrifugal pump malfunctions were obtained. Out of 350,000 cases completed with centrifugal pumps over a 23 month period, the FDA received reports of 68 malfunctions, 22 electrical burning smells, and three speed surges, yielding a failure rate of 1 in 3,763 cases. FDA records revealed five death reports and three serious injury reports. A survey was sent to 2,424 Society of Thoracic Surgeons' members to obtain more information; 285 who use centrifugal pumps responded. Sixty surgeons (21%) reported 108 malfunctions, including 46 complete pump failures. Fifty-one of 243 surgeons (21%) who use centrifugal pumps for bypass reported that perfusionists have forgotten to clamp the pump line, resulting in backflow. We conclude centrifugal pumps are generally safe, but malfunctions, low flows, and human errors can lead to retrograde flow and occasionally air embolization. There are valves that can be added to the bypass circuitry to prevent this risk.